养心生脉颗粒辅助治疗扩张性心肌病并心力衰竭的临床效果观察

发布时间：2018-05-31 17:57

本文选题：养心生脉颗粒 + 扩张性心肌病　；参考：《中药药理与临床》2017年03期

【摘要】：目的:观察养心生脉颗粒辅助治疗扩张性心肌病并心力衰竭的临床效果。方法:在2014年3月至2016年2月期间于我院心内科就诊的扩张性心肌病合并心力衰竭患者共72例,随机数字表法分成2组(各36例)。一组为对照组,给予常规治疗药物,另一组为观察组,在常规药物基础上加用养心生脉颗粒用以辅助治疗,分析该两组患者心功能指标和治疗疗效差异。结果:(1)观察组治疗后的总有效率为91.67%,明显高于对照组72.22%。治疗后,观察组血清脑钠肽(NT-Pro BNP)水平、左心射血分数(LVEF)和明尼苏达心力衰竭生活质量量表(ml HFFQ)得分分别为(513.0±14.8pg/ml、44.81±2.03%、49.51±5.24分),均明显优于对照组(669.1±15.2pg/ml、39.95±2.05%、59.82±5.81分)。(3)治疗后,观察组心输出量(CO)、6分钟步行试验(6MWT)和心率分别为(3.16±0.15L/min、474.5±18.5m、85.1±2.2次/min),均明显优于对照组(2.69±0.14L/min、419.5±17.3m、91.6±2.4次/min)。(4)治疗后,观察组左室收缩末期内径(LVSD)和左心室舒张末期内径(LVDD)分别为(41.02±1.86、51.28±2.41)mm,均明显小于对照组(46.80±2.01、58.00±2.59)mm。(5)治疗期间,观察组有11.11%的患者发生不良反应,低于对照组22.22%,但差异无统计学意义。结论:养心生脉颗粒可作为扩张性心肌病并心力衰竭的辅助用药,其可提高治疗疗效,改善患者心功能。
[Abstract]:Objective: to observe the clinical effect of Yangxin Shengmai granule in the treatment of dilated cardiomyopathy and heart failure. Methods: from March 2014 to February 2016, 72 patients with dilated cardiomyopathy complicated with heart failure were randomly divided into two groups (36 cases each). One group was the control group, and the other group was the observation group. The other group was treated with Yangxinshengmai granule on the basis of routine medicine. The difference of cardiac function index and therapeutic effect between the two groups was analyzed. Results the total effective rate of the observation group was 91.67, which was significantly higher than that of the control group (72.22%). After treatment, the levels of brain natriuretic peptide NT-Pro BNPs, left ventricular ejection fraction (LVEF) and Minnesota Heart failure quality of Life scale (HFFQs) were 513.0 卤14.8pgml / ml, 44.81 卤2.03g / ml and 49.51 卤5.24, respectively, which were significantly better than those in the control group (669.1 卤15.2pgml / ml 39.95 卤2.059.82 卤5.81). The cardiac output and heart rate were 3.16 卤0.15L / min, 474.5 卤18.5 mg / min and 85.1 卤2.2 / min, respectively, which were significantly better than those in the control group (2.69 卤0.14L / min 419.5 卤17.3 mm / min 91.6 卤2.4 times / min 路min ~ (4). The left ventricular end-systolic diameter (LVSD) and left ventricular end-diastolic diameter (LVDDD) were 41.02 卤1.86 卤51.28 卤2.41 mm respectively in the observation group, which were significantly lower than that in the control group (46.80 卤2.01g 58.00 卤2.59mm.) during the treatment period, 11.11% of the patients in the observation group had adverse reactions, which were lower than 22.22mm in the control group, but the difference was not statistically significant. Conclusion: Yangxinshengmai granule can be used as an adjuvant drug for dilated cardiomyopathy and heart failure.
【作者单位】：海口市第三人民医院;南昌大学医学院;内蒙古医科大学附属医院;
【分类号】：R259

【参考文献】